Institution · Acuitas Therapeutics (Canada)

Most cited papers from Acuitas Therapeutics (Canada)

Acuitas Therapeutics (Canada)

What are the most cited papers from Acuitas Therapeutics (Canada)?

The most cited paper from Acuitas Therapeutics (Canada) is "The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs" (Akin Akinc, Martin A. Maier, Muthiah A. Manoharan et al., 2019), with 1,651 citations. Next come "CAR T cells produced in vivo to treat cardiac injury" (1,352) and "Lipid Nanoparticle Systems for Enabling Gene Therapies" (1,190).

Published TypeFieldAccessCitations

Showing 50 of 59 papers. Every paper with more than 55 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs Akin Akinc, Martin A. Maier, Muthiah A. Manoharan et al. · Nature Nanotechnology Open access	Dec 2019	1,651
2	CAR T cells produced in vivo to treat cardiac injury Joel G. Rurik, István Tombácz, Amir Yadegari et al. · Science Open access	6 Jan 2022	1,352
3	Lipid Nanoparticle Systems for Enabling Gene Therapies Pieter R. Cullis, Michael J. Hope · Molecular Therapy Open access	13 Apr 2017	1,190
4	Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes Norbert Pardi, Steven Tuyishime, Hiromi Muramatsu et al. · Journal of Controlled Release Open access	8 Aug 2015	1,054
5	Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination Norbert Pardi et al. · Nature Open access	2 Feb 2017	903
6	In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates Kiran Musunuru et al. · Nature	19 May 2021	803
7	Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses Mohamad‐Gabriel Alameh et al. · Immunity Open access	4 Nov 2021	772
8	Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses Norbert Pardi et al. · The Journal of Experimental Medicine Open access	8 May 2018	536
9	Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals Andreas Theß, Stefanie E. Grund, Barbara L. Mui et al. · Molecular Therapy Open access	8 Jun 2015	528
10	Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles Barbara L. Mui, Ying K. Tam, Muthusamy Jayaraman et al. · Molecular Therapy — Nucleic Acids Open access	2013	504
11	Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice Paul F. McKay, Kai Hu, Anna K. Blakney et al. · Nature Communications Open access	9 Jul 2020	487
12	SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation Katlyn Lederer et al. · Immunity Open access	21 Nov 2020	404
13	A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice Dorottya I. Laczko et al. · Immunity Open access	30 Jul 2020	394
14	In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels Tanja Rothgangl et al. · Nature Biotechnology Open access	19 May 2021	389
15	A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes Claudia P. Arevalo, Marcus J. Bolton, Valerie Le Sage et al. · Science Open access	24 Nov 2022	368
16	Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA Sam Chen, Yuen Yi C. Tam, Paulo J.C. Lin et al. · Journal of Controlled Release	27 May 2016	367
17	Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge Norbert Pardi, Anthony J. Secreto, Xiaochuan Shan et al. · Nature Communications Open access	2 Mar 2017	359
18	Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease Kiran Musunuru et al. · New England Journal of Medicine Open access	15 May 2025	356
19	In vivo hematopoietic stem cell modification by mRNA delivery Laura Breda, Tyler Ellis Papp, Michael P. Triebwasser et al. · Science Open access	27 Jul 2023	334
20	A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice Alec W. Freyn, Jamile Ramos da Silva, Victoria C. Rosado et al. · Molecular Therapy Open access	19 Apr 2020	311
21	Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs István Tombácz, Dorottya I. Laczko, Hamna Shahnawaz et al. · Molecular Therapy Open access	4 Jun 2021	299
22	Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies Norbert Pardi, Kaela Parkhouse, Ericka Kirkpatrick et al. · Nature Communications Open access	16 Aug 2018	295
23	Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines Johannes Lutz, Sandra Lazzaro, Mohamed Habbeddine et al. · npj Vaccines Open access	10 Oct 2017	263
24	PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake Hamideh Parhiz, Vladimir V. Shuvaev, Norbert Pardi et al. · Journal of Controlled Release Open access	15 Oct 2018	238
25	Molecular fate-mapping of serum antibody responses to repeat immunization Ariën Schiepers, Marije F. L. van ’t Wout, Allison J. Greaney et al. · Nature Open access	16 Jan 2023	191
26	Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood–brain barrier Oscar Armando Marcos-Contreras et al. · Proceedings of the National Academy of Sciences Open access	31 Jan 2020	189
27	mRNA mediates passive vaccination against infectious agents, toxins, and tumors Moritz Thran, Jean Mukherjee, Marion Pönisch et al. · EMBO Molecular Medicine Open access	9 Aug 2017	172
28	Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration Sam Chen, Yuen Yi C. Tam, Paulo J.C. Lin et al. · Journal of Controlled Release	5 Oct 2014	162
29	Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA Fatima Rizvi, Elissa Everton, Anna R. Smith et al. · Nature Communications Open access	27 Jan 2021	159
30	Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice Jamile Ramos da Silva, Karine Bitencourt Rodrigues, Guilherme Formoso Pelegrin et al. · Science Translational Medicine Open access	3 Mar 2023	145
31	Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals Jennifer R Connors, David Joyner, Nathan J. Mege et al. · Communications Biology Open access	17 Feb 2023	116
32	In vivo cytidine base editing of hepatocytes without detectable off-target mutations in RNA and DNA Lukas Villiger, Tanja Rothgangl, Dominik Witzigmann et al. · Nature Biomedical Engineering Open access	25 Jan 2021	108
33	Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques Norbert Pardi, Celia C. LaBranche, Guido Ferrari et al. · Molecular Therapy — Nucleic Acids Open access	21 Mar 2019	107
34	ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines Magnus A. G. Hoffmann, Zhi Yong Yang, Kathryn E. Huey‐Tubman et al. · Cell Open access	21 Apr 2023	100
35	Anti-PfGARP activates programmed cell death of parasites and reduces severe malaria Dipak Kumar Raj et al. · Nature Open access	22 Apr 2020	96
36	Non-viral Delivery of Zinc Finger Nuclease mRNA Enables Highly Efficient In Vivo Genome Editing of Multiple Therapeutic Gene Targets Anthony Conway, Matthew C. Mendel, Kenneth H. Kim et al. · Molecular Therapy Open access	6 Mar 2019	95
37	Targeting lipid nanoparticles to the blood-brain barrier to ameliorate acute ischemic stroke Jia Nong et al. · Molecular Therapy Open access	7 Mar 2024	94
38	Expression Kinetics and Innate Immune Response after Electroporation and LNP-Mediated Delivery of a Self-Amplifying mRNA in the Skin Hanne Huysmans, Zifu Zhong, Joyca De Temmerman et al. · Molecular Therapy — Nucleic Acids Open access	7 Aug 2019	89
39	Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses Norbert Pardi, Juan Manuel Carreño, George O’Dell et al. · Nature Communications Open access	9 Aug 2022	88
40	Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice Katherine L. Mallory, Justin A. Taylor, Xiaoyan Zou et al. · npj Vaccines Open access	18 Jun 2021	86
41	Development of an mRNA-lipid nanoparticle vaccine against Lyme disease Matthew Pine, Gunjan Arora, Thomas M. Hart et al. · Molecular Therapy Open access	2 Aug 2023	85
42	A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection Mohamad‐Gabriel Alameh et al. · Science Open access	3 Oct 2024	83
43	mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice Zekun Mu et al. · Cell Reports Open access	Mar 2022	83
44	Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses Meagan McMahon, George O’Dell, Jessica Tan et al. · Proceedings of the National Academy of Sciences Open access	2 Nov 2022	82
45	mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model Chutamath Sittplangkoon, Mohamad‐Gabriel Alameh, Drew Weissman et al. · Frontiers in Immunology Open access	14 Oct 2022	81
46	Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics Sean C. Semple, Robert D. Leone, Christopher Barbosa et al. · Pharmaceutics Open access	11 Feb 2022	81
47	Liposomal Delivery of CTL Epitopes to Dendritic Cells Ghania Chikh, Marie-Paule Schutze-Redelmeir · Bioscience Reports	Apr 2002	78
48	Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus Colleen Furey, Gabrielle Scher, Naiqing Ye et al. · Nature Communications Open access	23 May 2024	76
49	A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets Koen van de Ven, Josien Lanfermeijer, Harry van Dijken et al. · Science Advances Open access	14 Dec 2022	70
50	Nucleoside-Modified mRNA Vaccines Protect IFNAR –/– Mice against Crimean-Congo Hemorrhagic Fever Virus Infection Sofia Appelberg, Lijo John, Norbert Pardi et al. · Journal of Virology Open access	24 Nov 2021	69

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.